Martijn Franssen

Nimbus Control BV (Nimbus) is an independent investment firm with headquarters in the Netherlands. Nimbus was founded in 1993 and has offices located in Munich, Germany and Brussels, Belgium.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Arlon Capital Partners Management Co. LLC (Arlon Capital Partners) is a private equity firm subsidiary of Arlon Group LLC founded in 2007. The firm is is headquartered in New York.

IBS Capital Management BV is an alternative investment manager based in the Netherlands. The Dutch company acts as an investment manager for alternative investments. Harold Knebel has been the CEO of the private company since 2016.

KplusV Startgreen Investment Services BV is an independent private equity firm with its headquarters in Amsterdam, the Netherlands. It was founded in 2013.

Nordian Capital BV(Nordian Capital), formerly known as Rabo Capital an independent Netherlands based private equity firm which was founded in September 2014 as a spinoff from Rabobank.

O2 Capital Partners (O2 Capital) is a private equity and venture capital firm founded in 2011 by Philip Sluiter, Bob van der Veen and Pieter van der Zanden. The firm headquartered in Oosterbeek, Netharlands.

Victus Participations BV is an Independent Private Equity firm founded in 2017. Victus Participations BV is headquartered in Amsterdam.

De Gentse Kluis SA engages in the supply of frozen ready to eat meals. The company was founded on July 5, 2006 and is headquartered in Veurne, Belgium.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.